Discovery of improper accounting treatment in prior years, restatement of financial results and special investigation expenses
First written in FY2023-Q1. 3 of 9 entries say "Worsened", first in FY2024-Q2. Latest entry: FY2026.
6 other companies' latest entry also says "Other".
- FY2026Continuing amended retrospective presentationAnnual report
「The figures for the 112th and 113th fiscal years reflect restatements due to the correction of errors in the figures approved at the annual general meetings of shareholders for the respective fiscal years.」
In connection with the improper accounting treatment in prior years, annual disclosures continue to reflect restatements due to the correction of errors in the key figures for the 112th and 113th fiscal years. - FY2024WorsenedAnnual report
「The fees for audit attestation services for the current consolidated fiscal year include ¥365 million in fees and other amounts for audit services relating to our restatements for prior years.」
Audit service fees of ¥365 million related to the improper accounting treatment and restatement of financial results for prior years were recognized, an increase from the ¥46 million disclosed for the previous fiscal year. - FY2024-Q3WorsenedAnnual report
「Accordingly, we recognized ¥155 million in special investigation expenses and other costs incurred by the External Investigation Committee during the nine months ended the third quarter of the current consolidated fiscal year as an extraordinary loss under special investigation expenses and other costs. Special investigation expenses and other costs incurred by the External Investigation Committee are expected to arise from the next consolidated quarter onward, but their amount cannot reasonably be estimated at present.」
The company recognized ¥155 million in external investigation expenses and other costs related to the improper accounting treatment in prior years and expects additional costs to arise, but states that their amount cannot reasonably be estimated. - FY2024-Q2WorsenedAnnual report
「Regarding the initial matter, we received an interim investigation report on 15 January 2024. ... As of the end of the previous consolidated fiscal year, we determined that an allowance for doubtful accounts of ¥3,916 million was required for long-term accounts receivable of ¥4,453 million. ... As the additional investigation is ongoing, figures and other information in the quarterly consolidated financial statements may change depending on the progress of the investigation.」
After receiving the External Investigation Committee's interim investigation report, the company determined that an allowance for doubtful accounts of ¥3,916 million was required for long-term accounts receivable of ¥4,453 million. It also disclosed that an additional investigation had begun, that amended reports for prior-year securities reports and other filings and quarterly reports were scheduled to be submitted, and that the financial figures could change. - FY2024-Q1No special investigation expenses or other costs recognized in the current periodAnnual report
「Special investigation expenses and other costs 57 -」
Special investigation expenses and other costs of ¥57 million recognized in the same period of the previous year in connection with the improper accounting treatment in prior years were not recognized during the three months ended the first quarter of the current fiscal year. - FY2023Disclosure of audit fees related to prior-year restatementsAnnual report
「The fees for audit attestation services for the current consolidated fiscal year include ¥46 million in fees and other amounts for audit services relating to our restatements for prior years.」
The company disclosed that the fees for audit attestation services for the current fiscal year include ¥46 million for the restatement audit related to the improper accounting treatment in prior years. - FY2023-Q3Increase in special investigation expenses and other costsAnnual report
「Special investigation expenses and other costs - 153」
Special investigation expenses and other costs related to the improper accounting treatment in prior years totaled ¥153 million, an increase from ¥149 million in the second quarter of FY2023. - FY2023-Q2Continued recognition of special investigation expenses and other costsAnnual report
「Special investigation expenses and other costs - 149」
In connection with the improper accounting treatment in prior years, special investigation expenses and other costs of ¥149 million were recognized as an extraordinary loss during the six months ended the second quarter of the current fiscal year. - FY2023-Q1First statedAnnual report
「Because it was discovered that inappropriate accounting treatment had been applied in previous fiscal years, the key management indicators and other figures for the cumulative first quarter of the 112th fiscal year are presented using the corrected financial results.」
Following the discovery of improper accounting treatment in prior years, key management indicators for the same period of the previous year are presented using the restated figures. Special investigation expenses and other costs of ¥57 million were recognized in the current quarter, while fraud-related losses of ¥159 million were recognized in the same period of the previous year.